PRODUCT USE IN UNAPPROVED INDICATION

This adverse event was reported 241070 times

These drugs are most commonly taken by patients reporting PRODUCT USE IN UNAPPROVED INDICATION:

# Drug Count
0 DUPILUMAB 41225
1 DICLOFENAC SODIUM 13274
2 PREDNISONE 13036
3 METHOTREXATE SODIUM 10741
4 ACETAMINOPHEN 10116
5 METHOTREXATE 10008
6 RITUXIMAB 7813
7 MYCOPHENOLATE MOFETIL HYDROCHLORIDE 7310
8 MYCOPHENOLATE MOFETIL 7290
9 CETIRIZINE HYDROCHLORIDE 6849
See all common drugs associated with PRODUCT USE IN UNAPPROVED INDICATION

PRODUCT USE IN UNAPPROVED INDICATION is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 IBUPROFEN, ACETAMINOPHEN 1717 0.6176
1 ALMOTRIPTAN 338 0.3353
2 CAPLACIZUMAB 573 0.3353
3 OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE 607 0.3052
4 IBUPROFEN, PHENYLEPHRINE HYDROCHLORIDE 289 0.2902
5 DUVELISIB 181 0.2366
6 ETHIODIZED OIL 291 0.2272
7 CETIRIZINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE 142 0.2219
8 DIHYDROERGOTAMINE MESYLATE 262 0.2066
9 CAFFEINE CITRATE 455 0.2013
See all drugs enriched for association with PRODUCT USE IN UNAPPROVED INDICATION

PRODUCT USE IN UNAPPROVED INDICATION is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Menin Inhibitor [EPC] 5 0.1042
1 Anthelmintic [EPC] 254 0.0882
2 Interleukin-4 Receptor alpha Antagonist [EPC] 41225 0.0861
3 Methylxanthine [EPC] 4902 0.0848
4 Polyene Antimicrobial [EPC] 30 0.0754
5 Antiparasitic [EPC] 472 0.0749
6 Pediculicide [EPC] 472 0.0730
7 Antileishmanial [EPC] 26 0.0686
8 Melanin Synthesis Inhibitor [EPC] 73 0.0649
9 RNA Synthetase Inhibitor Antibacterial [EPC] 840 0.0627
See all drug classes enriched for association with PRODUCT USE IN UNAPPROVED INDICATION